Meeting on the Mesa 2021 | Remaining issues in developing advanced therapies

Christian Schneider, MD, Biopharma Excellence, Munich, Germany, describes key challenges that need to be overcome in the development and commercialization of advanced therapies. Developers may face issues relying on previous research and safety data on vectors in gene therapy, due to the rapid evolution of research within the field. Dr Schneider additionally highlights the need for using animal models and potency assays predicative for humans, as well as cooperation within the industry to facilitate authorization and reimbursement. This interview took place at Meeting on the Mesa 2021.